심근경색(MI) 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2031년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for myocardial infarction (MI) therapeutics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global MI therapeutics market from 2024 to 2031.

Key Insights:

• MI Therapeutics Market Size (2024E): US$22.67 Bn
• Projected Market Value (2031F): US$30.3 Bn
• Global Market Growth Rate (CAGR 2024 to 2031):4.2%

MI Therapeutics Market - Report Scope:

Myocardial infarction, commonly known as a heart attack, is a leading cause of morbidity and mortality worldwide. MI therapeutics include a range of treatment modalities such as medications, surgical interventions, and lifestyle modifications aimed at managing acute myocardial infarction and preventing future cardiovascular events. The market serves hospitals, outpatient clinics, and rehabilitation centers, providing a variety of therapeutics, including antiplatelet agents, beta-blockers, ACE inhibitors, statins, and novel therapies like PCSK9 inhibitors. Market growth is driven by the increasing prevalence of cardiovascular diseases, advancements in therapeutic options, and rising healthcare expenditures.

Market Growth Drivers:

The global MI therapeutics market is propelled by several key factors, including the rising incidence of cardiovascular diseases due to lifestyle changes, aging populations, and the increasing prevalence of risk factors such as hypertension, diabetes, and obesity. Furthermore, the development of novel drug formulations and treatment strategies enhances therapeutic efficacy and patient outcomes. Growing awareness about the importance of early intervention and preventive measures also contributes to market expansion. Additionally, the expansion of healthcare infrastructure and improved access to cardiac care services play a crucial role in supporting market growth.

Market Restraints:

Despite promising growth prospects, the MI therapeutics market faces challenges related to high treatment costs, stringent regulatory approvals, and the need for continuous patient monitoring. The high costs associated with innovative therapeutics and advanced surgical procedures may limit access for certain patient populations, particularly in developing economies. Moreover, regulatory hurdles and the lengthy approval processes for new drugs can impede market entry for novel therapeutics. Ensuring patient adherence to prescribed treatment regimens also remains a challenge, as lifestyle modifications are crucial for preventing recurrent events.

Market Opportunities:

The MI therapeutics market presents significant growth opportunities driven by technological innovations, demographic trends, and evolving healthcare delivery models. The integration of digital health technologies, such as telehealth platforms and remote monitoring devices, enhances patient access to MI management services and improves adherence to treatment. Additionally, the growing focus on personalized medicine and tailored therapeutic approaches can stimulate innovation and expand treatment options. Strategic partnerships between pharmaceutical companies, healthcare providers, and research institutions are essential to capitalize on emerging opportunities and drive market advancements.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the MI therapeutics market globally?
• Which therapeutic classes and treatment modalities are gaining traction across different healthcare settings?
• How are technological advancements reshaping the competitive landscape of the MI therapeutics market?
• Who are the key players contributing to the MI therapeutics market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global MI therapeutics market?

Competitive Intelligence and Business Strategy:

Leading players in the global MI therapeutics market, including Pfizer Inc., Novartis AG, Johnson & Johnson, and AstraZeneca, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced therapeutics, including novel antiplatelet agents, beta-blockers, and emerging therapies for heart failure management. Collaborations with healthcare providers, academic institutions, and regulatory agencies facilitate market access and promote technology adoption. Moreover, an emphasis on clinical research, evidence-based practice, and patient education enhances market growth and improves patient outcomes in the rapidly evolving MI therapeutics landscape.

Key Companies Profiled:

• Pfizer Inc.
• Novartis AG
• Johnson & Johnson
• AstraZeneca
• Bristol-Myers Squibb Company
• Sanofi S.A.
• Bayer AG
• Boehringer Ingelheim GmbH
• Amgen Inc.
• Gilead Sciences, Inc.

Myocardial Infarction (MI) Therapeutics Market Segmentation

By Drug Type

• Antiplatelet Agents
• Glycoprotein IIb/IIIa Inhibitors
• Antithrombotic Agents
• Beta-adrenergic Blockers

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• East Asia
• South Asia & Pacific
• Middle East and Africa
• Latin America

Table of Contents

1. Executive Summary

• 1.1. Global Myocardial Infarction (MI) Therapeutics Market Snapshot, 2024-2031
• 1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Product Adoption Analysis
• 3.2. Technology Assessment
• 3.3. Regulatory Landscape
• 3.4. Value Chain Analysis
  • 3.4.1. List of Distribution Channel/Marketplaces
    • 3.4.1.1. Retail
    • 3.4.1.2. Audiology
    • 3.4.1.3. E-Commerce
  • 3.4.2. List of End User (Industry)
• 3.5. Key Deals and Mergers
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Global Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2023
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2024-2031
• 4.3. Global Myocardial Infarction (MI) Therapeutics Market Outlook: Drug Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Drug Type, 2019-2023
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
    • 4.3.3.1. Antiplatelet Agents
    • 4.3.3.2. Glycoprotein IIb/IIIa Inhibitors
    • 4.3.3.3. Antithrombotic Agents
    • 4.3.3.4. Beta-adrenergic Blockers
• 4.4. Market Attractiveness Analysis: Drug Type
• 4.5. Global Myocardial Infarction (MI) Therapeutics Market Outlook: Route of Administration
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn) Analysis, By Route of Administration, 2019-2023
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
    • 4.5.3.1. Oral
    • 4.5.3.2. Injectable
• 4.6. Market Attractiveness Analysis: Route of Administration
• 4.7. Global Myocardial Infarction (MI) Therapeutics Market Outlook: Distribution Channel
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2023
  • 4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
    • 4.7.3.1. Hospitals
    • 4.7.3.2. Clinics
    • 4.7.3.3. Retail Pharmacies
    • 4.7.3.4. Online Pharmacies
• 4.8. Market Attractiveness Analysis: Distribution Channel

5. Global Myocardial Infarction (MI) Therapeutics Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2024-2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 6.1. Key Highlights
• 6.2. Pricing Analysis
• 6.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 6.3.1. By Country
  • 6.3.2. By Drug Type
  • 6.3.3. By Route of Administration
  • 6.3.4. By Distribution Channel
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 6.4.1. U.S.
  • 6.4.2. Canada
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 6.5.1. Antiplatelet Agents
  • 6.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 6.5.3. Antithrombotic Agents
  • 6.5.4. Beta-adrenergic Blockers
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 6.6.1. Oral
  • 6.6.2. Injectable
• 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 6.7.1. Hospitals
  • 6.7.2. Clinics
  • 6.7.3. Retail Pharmacies
  • 6.7.4. Online Pharmacies
• 6.8. Market Attractiveness Analysis

7. Europe Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 7.1. Key Highlights
• 7.2. Pricing Analysis
• 7.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 7.3.1. By Country
  • 7.3.2. By Drug Type
  • 7.3.3. By Route of Administration
  • 7.3.4. By Distribution Channel
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. U.K.
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Russia
  • 7.4.7. Turkiye
  • 7.4.8. Rest of Europe
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 7.5.1. Antiplatelet Agents
  • 7.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 7.5.3. Antithrombotic Agents
  • 7.5.4. Beta-adrenergic Blockers
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 7.6.1. Oral
  • 7.6.2. Injectable
• 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 7.7.1. Hospitals
  • 7.7.2. Clinics
  • 7.7.3. Retail Pharmacies
  • 7.7.4. Online Pharmacies
• 7.8. Market Attractiveness Analysis

8. East Asia Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 8.1. Key Highlights
• 8.2. Pricing Analysis
• 8.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 8.3.1. By Country
  • 8.3.2. By Drug Type
  • 8.3.3. By Route of Administration
  • 8.3.4. By Distribution Channel
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. South Korea
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 8.5.1. Antiplatelet Agents
  • 8.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 8.5.3. Antithrombotic Agents
  • 8.5.4. Beta-adrenergic Blockers
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 8.6.1. Oral
  • 8.6.2. Injectable
• 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 8.7.1. Hospitals
  • 8.7.2. Clinics
  • 8.7.3. Retail Pharmacies
  • 8.7.4. Online Pharmacies
• 8.8. Market Attractiveness Analysis

9. South Asia and Oceania Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 9.1. Key Highlights
• 9.2. Pricing Analysis
• 9.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 9.3.1. By Country
  • 9.3.2. By Drug Type
  • 9.3.3. By Route of Administration
  • 9.3.4. By Distribution Channel
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 9.4.1. India
  • 9.4.2. Southeast Asia
  • 9.4.3. ANZ
  • 9.4.4. Rest of South Asia & Oceania
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 9.5.1. Antiplatelet Agents
  • 9.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 9.5.3. Antithrombotic Agents
  • 9.5.4. Beta-adrenergic Blockers
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 9.6.1. Oral
  • 9.6.2. Injectable
• 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 9.7.1. Hospitals
  • 9.7.2. Clinics
  • 9.7.3. Retail Pharmacies
  • 9.7.4. Online Pharmacies
• 9.8. Market Attractiveness Analysis

10. North America Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 10.1. Key Highlights
• 10.2. Pricing Analysis
• 10.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 10.3.1. By Country
  • 10.3.2. By Drug Type
  • 10.3.3. By Route of Administration
  • 10.3.4. By Distribution Channel
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 10.4.1. Brazil
  • 10.4.2. Mexico
  • 10.4.3. Rest of Latin America
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 10.5.1. Antiplatelet Agents
  • 10.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 10.5.3. Antithrombotic Agents
  • 10.5.4. Beta-adrenergic Blockers
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 10.6.1. Oral
  • 10.6.2. Injectable
• 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 10.7.1. Hospitals
  • 10.7.2. Clinics
  • 10.7.3. Retail Pharmacies
  • 10.7.4. Online Pharmacies
• 10.8. Market Attractiveness Analysis

11. Middle East & Africa Myocardial Infarction (MI) Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 11.1. Key Highlights
• 11.2. Pricing Analysis
• 11.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 11.3.1. By Country
  • 11.3.2. By Drug Type
  • 11.3.3. By Route of Administration
  • 11.3.4. By Distribution Channel
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 11.4.1. GCC Countries
  • 11.4.2. Egypt
  • 11.4.3. South Africa
  • 11.4.4. Northern Africa
  • 11.4.5. Rest of Middle East & Africa
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Type, 2024-2031
  • 11.5.1. Antiplatelet Agents
  • 11.5.2. Glycoprotein IIb/IIIa Inhibitors
  • 11.5.3. Antithrombotic Agents
  • 11.5.4. Beta-adrenergic Blockers
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 11.6.1. Oral
  • 11.6.2. Injectable
• 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 11.7.1. Hospitals
  • 11.7.2. Clinics
  • 11.7.3. Retail Pharmacies
  • 11.7.4. Online Pharmacies
• 11.8. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Bayer HealthCare LLC
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Boehringer Ingelheim International GmbH
    • 12.3.2.1. Overview
    • 12.3.2.2. Segments and Products
    • 12.3.2.3. Key Financials
    • 12.3.2.4. Market Developments
    • 12.3.2.5. Market Strategy
  • 12.3.3. Eli Lilly and Company
    • 12.3.3.1. Overview
    • 12.3.3.2. Segments and Products
    • 12.3.3.3. Key Financials
    • 12.3.3.4. Market Developments
    • 12.3.3.5. Market Strategy
  • 12.3.4. Janssen Biotech, Inc.
    • 12.3.4.1. Overview
    • 12.3.4.2. Segments and Products
    • 12.3.4.3. Key Financials
    • 12.3.4.4. Market Developments
    • 12.3.4.5. Market Strategy
  • 12.3.5. Merck & Co. Inc.
    • 12.3.5.1. Overview
    • 12.3.5.2. Segments and Products
    • 12.3.5.3. Key Financials
    • 12.3.5.4. Market Developments
    • 12.3.5.5. Market Strategy
  • 12.3.6. Novartis International AG
    • 12.3.6.1. Overview
    • 12.3.6.2. Segments and Products
    • 12.3.6.3. Key Financials
    • 12.3.6.4. Market Developments
    • 12.3.6.5. Market Strategy
  • 12.3.7. Sanofi
    • 12.3.7.1. Overview
    • 12.3.7.2. Segments and Products
    • 12.3.7.3. Key Financials
    • 12.3.7.4. Market Developments
    • 12.3.7.5. Market Strategy
  • 12.3.8. AstraZeneca
    • 12.3.8.1. Overview
    • 12.3.8.2. Segments and Products
    • 12.3.8.3. Key Financials
    • 12.3.8.4. Market Developments
    • 12.3.8.5. Market Strategy
  • 12.3.9. Pfizer
    • 12.3.9.1. Overview
    • 12.3.9.2. Segments and Products
    • 12.3.9.3. Key Financials
    • 12.3.9.4. Market Developments
    • 12.3.9.5. Market Strategy
  • 12.3.10. Amgen, Inc
    • 12.3.10.1. Overview
    • 12.3.10.2. Segments and Products
    • 12.3.10.3. Key Financials
    • 12.3.10.4. Market Developments
    • 12.3.10.5. Market Strategy
  • 12.3.11. GlaxoSmithKline PLC
    • 12.3.11.1. Overview
    • 12.3.11.2. Segments and Products
    • 12.3.11.3. Key Financials
    • 12.3.11.4. Market Developments
    • 12.3.11.5. Market Strategy
  • 12.3.12. Regeneron Pharmaceuticals Inc.
    • 12.3.12.1. Overview
    • 12.3.12.2. Segments and Products
    • 12.3.12.3. Key Financials
    • 12.3.12.4. Market Developments
    • 12.3.12.5. Market Strategy
  • 12.3.13. Bristol-Myers Squibb Company
    • 12.3.13.1. Overview
    • 12.3.13.2. Segments and Products
    • 12.3.13.3. Key Financials
    • 12.3.13.4. Market Developments
    • 12.3.13.5. Market Strategy
  • 12.3.14. Alnylam Pharmaceuticals Inc.
    • 12.3.14.1. Overview
    • 12.3.14.2. Segments and Products
    • 12.3.14.3. Key Financials
    • 12.3.14.4. Market Developments
    • 12.3.14.5. Market Strategy

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations